March 20 (Reuters) - The UK's anti-trust regulator said on Monday that hearing device maker Cochlear (COH) and Copenhagen-based Demant DEMANT.CO had denied that the Australian firm's purchase of Demant's hearing implants business would lead to any competition concerns.
The Competition and Markets Authority (CMA) said in a statement that both Demant and Cochlear contested the regulator's Phase 1 findings that other hearing solutions are not good alternatives for bone conduction implants.
The CMA has set a June 5 deadline for its in-depth phase 2 probe into Cochlear's purchase of Demant's Oticon Medical business.
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$317.00 |
Change
4.170(1.33%) |
Mkt cap ! $20.73B | |||
| Open | High | Low | Value | Volume |
| $314.28 | $318.91 | $313.71 | $43.40M | 137.0K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 6 | 324 | $317.00 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $317.18 | 55 | 1 |
View Market Depth
| Last trade - 16.10pm 28/07/2025 (20 minute delay) ? |
| COH (ASX) Chart |